Indonesia

Population 2018: 268 million

### Tuberculosis profile

#### Estimates of TB burden, 2018

<table>
<thead>
<tr>
<th>Estimate</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total TB incidence</strong></td>
<td>845 (770–923)</td>
<td>316 (288–345)</td>
</tr>
<tr>
<td><strong>HIV-positive TB incidence</strong></td>
<td>21 (8.9–38)</td>
<td>7.9 (3.3–14)</td>
</tr>
<tr>
<td><strong>MDR/RR-TB incidence</strong></td>
<td>24 (17–32)</td>
<td>8.8 (6.2–12)</td>
</tr>
<tr>
<td><strong>HIV-negative TB mortality</strong></td>
<td>93 (67–99)</td>
<td>35 (33–37)</td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td>5.3 (2.1–9.8)</td>
<td>2 (0.79–3.7)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases</td>
<td>2.4% (1.8–3.3)</td>
</tr>
<tr>
<td>Previously treated cases</td>
<td>13% (9–18)</td>
</tr>
</tbody>
</table>

#### TB case notifications, 2018

- **Total new and relapse**: 563,879
  - % tested with rapid diagnostics at time of diagnosis: 12%
  - % with known HIV status: 37%
  - % pulmonary: 88%
  - % bacteriologically confirmed: 50%
  - % children aged 0-14 years: 11%
  - % women: 37%
  - % men: 52%
- **Total cases notified**: 570,289

#### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2018**: 67% (61–73)
- **TB patients facing catastrophic total costs**: 12% (10–13)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 12% (10–13)
- **Patients with known HIV status who are HIV-positive**
  - % on antiretroviral therapy: 4,082 (40%)

#### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 33%
  - New cases: 127%
  - Previously treated cases: 17%
- **Laboratory-confirmed cases**
  - MDR/RR-TB: 9,038
  - XDR-TB: 80
- **Patients started on treatment**
  - MDR/RR-TB: 4,194
  - XDR-TB: 59

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 10%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 10% (9.3–11)

#### TB financing, 2019

- **National TB budget (US$ millions)**: 365
  - Funding source: 30% domestic, 13% international, 57% unfunded

---

© Ranges represent uncertainty intervals

ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

ººº Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-01-11

Data: www.who.int/tb/data